Invention Grant
- Patent Title: Highly selective c-Met inhibitors as anticancer agents
-
Application No.: US14424395Application Date: 2013-08-01
-
Publication No.: US09695175B2Publication Date: 2017-07-04
- Inventor: Boyu Zhong , Chuan Shih , Hongbin Yuan , Feng Zhou
- Applicant: Crown Bioscience Inc. (Taiwan)
- Applicant Address: KY Grand Cayman
- Assignee: CB THERAPEUTICS INC.
- Current Assignee: CB THERAPEUTICS INC.
- Current Assignee Address: KY Grand Cayman
- Agency: Jun He Law Offices P.C.
- Agent James J. Zhu
- Priority: CN201210322359 20120903
- International Application: PCT/CN2013/080598 WO 20130801
- International Announcement: WO2014/032498 WO 20140306
- Main IPC: C07D487/04
- IPC: C07D487/04 ; C07D471/04 ; C07D513/04

Abstract:
Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.
Public/Granted literature
- US20150218171A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS Public/Granted day:2015-08-06
Information query